Novartis AG
NVS
$147.85
$4.913.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.25% | 17.11% | -18.24% | -15.59% | -15.65% |
| Total Depreciation and Amortization | 4.14% | 3.15% | 147.08% | 124.01% | 107.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.18% | 20.19% | 338.13% | 483.13% | 322.85% |
| Change in Net Operating Assets | -41.92% | -68.78% | 54.99% | 42.03% | 36.33% |
| Cash from Operations | 0.93% | 8.66% | 31.93% | 37.99% | 38.01% |
| Capital Expenditure | -17.73% | -13.32% | -23.31% | -26.86% | -24.49% |
| Sale of Property, Plant, and Equipment | -91.58% | -84.88% | -70.94% | -76.68% | -56.82% |
| Cash Acquisitions | -296.00% | 27.43% | 39.33% | 69.25% | 0.40% |
| Divestitures | -160.99% | -182.24% | 244.07% | 343.75% | 740.91% |
| Other Investing Activities | 80.15% | 85.44% | -44.40% | -1,402.34% | -11.48% |
| Cash from Investing | -169.62% | 35.09% | 6.96% | 34.14% | -6.08% |
| Total Debt Issued | 145.39% | -15.69% | -82.11% | 5.07% | 310.19% |
| Total Debt Repaid | 28.26% | -20.44% | 26.57% | 39.18% | -30.14% |
| Issuance of Common Stock | -16.13% | -10.00% | -23.33% | 4.00% | -- |
| Repurchase of Common Stock | 15.85% | -10.57% | -53.76% | -97.39% | -43.40% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -12.03% | -2.54% | -2.54% | -2.54% | -48.84% |
| Other Financing Activities | -38.15% | -42.03% | -645.00% | -110.37% | -104.78% |
| Cash from Financing | 81.89% | -26.61% | -108.98% | -74.83% | -47.71% |
| Foreign Exchange rate Adjustments | 3,887.50% | 293.29% | 28.41% | 355.42% | 106.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.13% | 98.76% | -436.63% | 58.18% | 5.06% |